Evidence map›Paper›PMID 41855094›Full record

GuidelineJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2026

S3 guideline diagnostics and therapy of alopecia areata - Part 1: Diagnostics and epidemiology.

Ulrike Blume-Peytavi, Andria Constantinou, Tsenka Tomova-Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens and 4 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ulrike Blume-PeytaviDepartment of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.ORCID https://orcid.org/0000-0003-3528-3752
Andria ConstantinouDepartment of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.ORCID https://orcid.org/0000-0002-6569-8636
Tsenka Tomova-SimitchievaDepartment of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.ORCID https://orcid.org/0000-0002-5864-7857
Adrian TanewPrivate practice, Vienna, Austria.ORCID https://orcid.org/0000-0002-4433-2790
Michael SticherlingDepartment of Dermatology, University Hospital Erlangen, Erlangen, Germany.ORCID https://orcid.org/0000-0001-9396-3938
Hermann GirschickDepartment of Pediatrics and Adolescent Medicine, Vivantes Netzwerk für Gesundheit GmbH, Klinikum im Friedrichshain, Berlin, Germany.ORCID https://orcid.org/0000-0002-2755-3129
Annika VogtDepartment of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.ORCID https://orcid.org/0000-0001-9134-8413
Uwe SchwichtenbergDerma Nord Dermatology Practice, Bremen, Germany.
Uwe GielerPsychodermatology Competence Center, University Hospital Giessen, Vitos Giessen-Marburg gemeinnützige GmbH, Vitos Psychosomatik Giessen, Giessen, Germany.ORCID https://orcid.org/0000-0003-0546-3269
André MärtensHairdresser, Berlin, Germany.
Kerstin ZienertAlopecia Areata Deutschland e.V., Krefeld, Germany.
Claudia StendersAlopecia Areata Deutschland e.V., Krefeld, Germany.
Ricardo Niklas WernerDepartment of Dermatology, Venereology and Allergology, Division of Evidence-Based Medicine (dEBM), Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.ORCID https://orcid.org/0000-0003-3209-1392
Doris WilbornDepartment of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.ORCID https://orcid.org/0000-0001-6966-5279

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the project funded by the Innovation Committee at the G-BA, the S3 guideline for the diagnosis and treatment of AA was developed between 2023 and 2025. The interdisciplinary expert panel consisted of representatives from the German Dermatological Society, in particular from the Pediatric Dermatology Working Group, the Professional Association of German Dermatologists, the German Society for Psychosomatic Medicine and Psychotherapy, the German Society for Pediatrics and Adolescent Medicine, the Austrian Society for Dermatology and Venereology, a hairdresser as an external consultant and two patient representatives. In the first of two parts, we present the key statements on epidemiology and the recommendations for diagnosis. Data from Germany show a population-based prevalence of AA of 0.22% (95% CI 0.21-0.22) for 2016 and 0.21% (95% CI 0.20-0.22) for 2020. This means that 170,000 people in Germany were diagnosed with alopecia areata (AA) in 2020. International data show a pooled prevalence of 2.1%, but with large regional differences. Data on the incidence of AA from Germany show that 72 patients per 100,000 were newly diagnosed with AA in 2020 (RR 0.072%; 95% CI 0.07-0.08). Extrapolated to the German population, this means that around 70,000 people were newly diagnosed with AA in 2020.

Indexed as

Alopecia AreataAdolescentAdultChildDermatologyFemaleGermanyHumansIncidenceMalePrevalenceAlopecia areatacomorbiditiesdiagnosisepidemiologyprognostic factorsrisk factors

Identifiers

PMID41855094
PMCPMC13340965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.